financetom
Business
financetom
/
Business
/
Why Is Madison Square Garden Entertainment Stock Trading Higher Today?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Is Madison Square Garden Entertainment Stock Trading Higher Today?
Nov 6, 2025 10:23 AM

Madison Square Garden Entertainment ( MSGE ) stock gained after it reported its fiscal first-quarter 2026 results. Through the trading session, the stock gave up its gains.

MSGE is showing positive momentum. Get the latest updates here

The quarterly revenue rose by 14% year-on-year (Y/Y) to $158.26 million, topping the analyst consensus estimate of $156.80 million. 

Earnings loss per share of 46 cents beat the analyst consensus loss estimate of 63 cents.

Also Read: Madison Square Garden Takes Hit From Concert Slowdown, Stock Falls

Revenues from entertainment offerings increased 14% Y/Y to $131.3 million. It reflected an increase in the number of concerts at the company's theaters and at The Garden.

According to the company, it included a new record for the number of concerts in any quarter at the Madison Square Garden Arena.

After the end of the quarter, the New York Knicks ("Knicks") and New York Rangers ("Rangers") began their 2025-26 regular seasons at The Garden.

Soon, the Christmas Spectacular production kicks off its 2025 holiday season at Radio City Music Hall with 215 planned performances as compared to 200 in fiscal 2025.

Food, beverage, and merchandise revenues rose 20% Y/Y to $22.8 million.

The company reported an adjusted operating income of $7.1 million, versus $1.9 million profit a year ago, primarily due to higher revenues. 

As of September 30, cash and equivalents stood at $30.47 million.

Executive Chairman and CEO James L. Dolan noted strong momentum across its business, including for bookings and this year's Christmas Spectacular production. He expressed optimism in the company's ability to drive solid growth in both revenue and adjusted operating income in fiscal 2026.

MSGE Price Action: Madison Square Garden shares were up 0.05% at $44.56 at the time of publication on Thursday, according to Benzinga Pro data.

Read Next:

Alibaba AI Crushes Rivals In Crypto Trading, Matches GPT-5 In Math

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved